Simulations Plus (SLP) Saham Harga
Simulations Plus Harga
Selama 19 tahun terakhir pendapatan Simulations Plus tumbuh 14,7% per tahun, mencapai 79,18 Juta. USD. Laba per saham tumbuh 15,0% per tahun selama 18 tahun terakhir. Bagi Simulations Plus, margin bersih sebesar -81,7% turun dibanding 21,1% beberapa tahun lalu. Pada harga saat ini imbal hasil dividen sekitar 0,97%. Rasio pembayaran sekitar 37% dari laba. Target harga konsensus 12 bulan untuk Simulations Plus adalah 18,50 USD, sekitar di atas harga saat ini 0,0%. Dari 12 analis, 0 merekomendasikan beli — konsensus keseluruhan Jual.
Harga saham Simulations Plus
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Simulations Plus
Pertanyaan yang sering diajukan tentang saham Simulations Plus
Simulations Plus Inc is primarily active in the pharmaceutical and biotechnology industries. With a focus on simulation software and consulting services, the company provides cutting-edge solutions for drug discovery and development. Simulations Plus Inc's expertise in modeling and simulation technologies helps pharmaceutical companies optimize their drug formulation and dosage strategies. By leveraging their industry-leading software platforms, Simulations Plus Inc supports the efficient research and development of new therapies, enhancing the overall success and effectiveness of pharmaceutical companies.
The main competitors of Simulations Plus Inc in the market include Certara, Inc and Dassault Systèmes.
The business model of Simulations Plus Inc revolves around providing software and consulting services for pharmaceutical research and development. As a leading provider in the field of drug discovery and development, Simulations Plus Inc aims to enhance the efficiency and effectiveness of the pharmaceutical industry through their innovative solutions. By utilizing computer modeling and simulation software, the company assists in predicting and optimizing drug properties, interactions, and outcomes. This enables scientists and researchers to make informed decisions throughout the drug development process, leading to improved efficacy, safety, and reduced costs. Simulations Plus Inc's comprehensive solutions cater to the needs of pharmaceutical companies, regulatory agencies, and academia worldwide.
Simulations Plus Inc is a leading provider of simulation and modeling software for the pharmaceutical and biotechnology industries. Established in 1996, the company has amassed extensive expertise in the field. Simulations Plus Inc has developed a strong reputation for its cutting-edge technology and innovative solutions, helping pharmaceutical companies optimize drug discovery and development processes. With a focus on increasing efficiency and reducing costs, Simulations Plus Inc has become a trusted partner for numerous organizations worldwide. The company's commitment to excellence has earned them recognition and a loyal customer base. Simulations Plus Inc continues to drive advancements in the industry, delivering impactful software solutions that streamline drug development.
Simulations Plus Inc has achieved significant milestones throughout its history. Some notable accomplishments include the development and release of their industry-leading software solutions, such as GastroPlus™ and DDDPlus™, which have gained widespread recognition and adoption in the pharmaceutical industry. The company has also formed strategic partnerships and collaborations with top pharmaceutical companies, further establishing its presence and credibility in the market. Additionally, Simulations Plus Inc has a strong track record of achieving consistent revenue growth and delivering value to its shareholders. These achievements reflect the company's commitment to innovation, excellence, and meeting the evolving needs of the life sciences industry.
Simulations Plus Inc is primarily present in the United States.
Simulations Plus Inc represents values of innovation, scientific excellence, and customer satisfaction. With a corporate philosophy focused on advancing pharmaceutical research and enhancing drug development, Simulations Plus Inc strives to provide cutting-edge software and consulting services. By combining advanced technologies and domain knowledge, the company facilitates cost-effective and efficient drug discovery and development processes. Simulations Plus Inc is committed to delivering high-quality solutions, fostering collaborative relationships, and continuously improving its products and services.
Analis saat ini menetapkan target harga rata-rata 18,50 USD untuk saham Simulations Plus (median: 18,50 USD), yaitu +0,0 % terhadap harga terbaru. Konsensus didasarkan pada 12 peringkat analis.
12 analis saat ini menilai saham Simulations Plus: 0 merekomendasikan beli, 7 tahan, dan 5 jual. Untuk 2026, analis memperkirakan Simulations Plus menghasilkan pendapatan 81,80 Juta. USD dan laba per saham 0,82 USD.
Dengan kurs saat ini, saham Simulations Plus diperdagangkan pada 16,46 EUR (18,50 USD).
Saham Simulations Plus (SLP) tercatat di 1 bursa, termasuk: NASDAQ (SLP).
Simulations Plus Inc. is a leading company in the field of simulation technology and software development. It provides solutions for researchers and experts in various industries, including biotechnology, pharmaceuticals, agriculture, food technology, and more. The company offers a range of products and tools for data analysis and innovative strategy development to bring new products and applications to the market. Some of its notable products include PK-SIM, MoBi, ADMET Predictor, GastroPlus, DILIsym, and MedChem Studio. Simulations Plus also offers solutions for the agricultural sector, such as Cartagenia, Crop Laptop, and Dose Response Toxicology. The company provides training and support to its customers, aiming to optimize their business processes. Its business model focuses on processing and analyzing large data sets to provide relevant insights and support decision-making processes. Simulations Plus aims to expand into new markets and develop products based on the latest technological advancements.
Pendapatan diperkirakan dari Simulations Plus adalah 81,80 Juta. USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Simulations Plus adalah 16,48 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Simulations Plus saat ini adalah 22,69. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Simulations Plus.
Rasio harga-terhadap-penjualan (PSR) Simulations Plus saat ini adalah 4,57. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Simulations Plus.
Skor Kualitas AlleAktien untuk Simulations Plus adalah 4/10.
ISIN dari Simulations Plus adalah US8292141053. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Simulations Plus adalah 924294. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Simulations Plus adalah SLP. Simbol ticker digunakan untuk memperdagangkan saham Simulations Plus di bursa saham.
Saham Simulations Plus
Kelompok Peer Simulations Plus
Simulations Plus Ticker
Simulations Plus FIGI
Semua metrik fundamental dan analisis mendalam Simulations Plus
Analisis saham kami untuk saham Simulations Plus mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Simulations Plus. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.